Immunic initiated with a Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Immunic (IMUX) with a Buy rating and $3 price target The firm says the company has “potential best-in-indication advantages” of vidofludimus calcium in relapsing-remitting multiple sclerosis and progressive multiple sclerosis. This is validated by Immunic’s Phase 2 data that demonstrated simultaneous anti-inflammation and neuroprotection, the analyst tells investors in a research note.